NasdaqCM - Delayed Quote USD

GlycoMimetics, Inc. (GLYC)

0.1766

-0.0172

(-8.88%)

At close: June 9 at 4:00:01 PM EDT

0.1781

+0.00

+(0.85%)

After hours: June 9 at 7:53:03 PM EDT

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

ROCKVILLE, Md., June 05, 2025--GlycoMimetics, Inc. (Nasdaq: GLYC) ("GlycoMimetics") today announced that its stockholders have approved the proposed merger (the "Merger") with Crescent Biopharma, Inc. ("Crescent"), along with all proposals related to the Merger. The proposals were voted upon at GlycoMimetics’ special meeting in lieu of the annual meeting of stockholders held on June 5, 2025 (the "Special Meeting"), including a reverse stock split of GlycoMimetics’ common stock to be effected at

Business Wire 4 days ago

GLYC
-8.88%
GlycoMimetics: Q1 Earnings Snapshot

MONROVIA, Md. AP) — GlycoMimetics Inc. GLYC) on Wednesday reported a loss of $2.3 million in its first quarter.

Associated Press Finance 26 days ago

GLYC
-8.88%
US Penny Stocks To Watch In February 2025

As the U.S. stock market navigates a mixed trading environment, with indices like the S&P 500 retreating slightly from record highs, investors are keeping an eye on smaller opportunities that might offer potential value. Penny stocks, though often associated with higher risk due to their smaller size and less-established nature, can still present intriguing investment possibilities when backed by strong financials and growth prospects. In light of current market conditions, we explore three...

Simply Wall St. 3 months ago

GLYC
-8.88%

GSIT
GlycoMimetics and Crescent Biopharma Announce Merger Plans

GlycoMimetics ( (GLYC) ) has shared an update. GlycoMimetics and Crescent Biopharma have updated their investor presentation related to their proposed merger. This presentation highlights that the merger is not a solicitation for any securities transaction. GlycoMimetics plans to file relevant materials with the SEC, including a proxy statement, urging investors to review these documents carefully. Crescent Biopharma, launched by Paragon Therapeutics, focuses on advancing cancer therapies, parti

TipRanks 4 months ago

GLYC
-8.88%
GlycoMimetics: Q3 Earnings Snapshot

ROCKVILLE, Md. AP) — GlycoMimetics Inc. GLYC) on Wednesday reported a loss of $9.8 million in its third quarter.

Associated Press Finance 6 months ago

GLYC
-8.88%
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT.

PR Newswire 6 months ago

GLYC
-8.88%
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

ROCKVILLE, Md., November 06, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, on December 7-10, 2024.

Business Wire 6 months ago

GLYC
-8.88%
US Penny Stocks To Watch In October 2024

As the U.S. stock market continues its upward trajectory with major indices like the Nasdaq hitting record highs, investors are keenly analyzing corporate earnings and economic data to gauge future opportunities. In this context, penny stocks—often representing smaller or newer companies—remain an intriguing area for those looking beyond established giants. Despite their name suggesting a bygone era, these stocks can offer significant potential when backed by strong financials and strategic...

Simply Wall St. 7 months ago

CVAC

GLYC
-8.88%

HNST
GlycoMimetics Announces Merger with Crescent Biopharma

GlycoMimetics ( (GLYC) ) has issued an update. GlycoMimetics, Inc. has announced a merger with Crescent Biopharma, aiming to enhance their presence in the biopharma sector. This merger, structured as a tax-free reorganization, will result in Crescent’s shareholders owning a significant majority of the combined entity. The transaction includes a substantial private placement of $200 million to support future growth and development. Both companies’ boards have approved the merger, expected to clos

TipRanks 7 months ago

GLYC
-8.88%
GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

ROCKVILLE, Md., October 29, 2024--GlycoMimetics, Inc. (NASDAQ: GLYC) announced today it has entered into an acquisition agreement with Crescent Biopharma, Inc. ("Crescent"), a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. Upon completion of the transaction, the Company plans to operate under the name Crescent Biopharma, Inc.

Business Wire 7 months ago

GLYC
-8.88%
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

ROCKVILLE, Md., October 29, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the Phase 2 analysis of the adaptive Phase 2/3 study of uproleselan being conducted by the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology in adults with newly diagnosed acute myeloid leukemia (AML) who are 60 years or older and fit for inten

Business Wire 7 months ago

GLYC
-8.88%
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

ROCKVILLE, Md., July 25, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the initiation of a strategic review and corporate restructuring plan. GlycoMimetics has engaged Lucid Capital Markets to act as a strategic advisor in the process.

Business Wire 10 months ago

GLYC
-8.88%
7 Sorry Biotech Stocks Set to Make Investors Sad

Biotech stocks are not for everyone, let’s make that perfectly clear. It’s challenging to invest in a field in which companies – particularly startups – can go for years without seeing a penny of revenue. While there are several outstanding companies from which to choose, the field is also littered with biotech stocks to sell before you get into too much trouble. Biotech stocks represent companies that are in the medical field. They develop and commercialize new medical treatments, drugs, and te

InvestorPlace 10 months ago

TNXP

OVID

GANX
Senior VP & Chief Medical Officer of GlycoMimetics Edwin Rock Buys 81% More Shares

Whilst it may not be a huge deal, we thought it was good to see that the GlycoMimetics, Inc. ( NASDAQ:GLYC ) Senior VP...

Simply Wall St. 11 months ago

GLYC
-8.88%

Performance Overview

Return	GLYC	S&P 500 (^GSPC)
YTD	-29.36%	+2.11%
1-Year	-32.08%	+12.32%
3-Year	-73.64%	+49.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

GlycoMimetics, Inc. (GLYC)

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

GlycoMimetics: Q1 Earnings Snapshot

US Penny Stocks To Watch In February 2025

GlycoMimetics and Crescent Biopharma Announce Merger Plans

GlycoMimetics: Q3 Earnings Snapshot

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

US Penny Stocks To Watch In October 2024

GlycoMimetics Announces Merger with Crescent Biopharma

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

7 Sorry Biotech Stocks Set to Make Investors Sad

Senior VP & Chief Medical Officer of GlycoMimetics Edwin Rock Buys 81% More Shares

Performance Overview